265 results about "Peptide binding" patented technology

An MHCl binding peptide design method based on evolutionary information and a Transform neural network algorithm relates to the field of protein design, and comprises the following steps: S1, extracting evolutionary information features of alleles of MHCII molecules and binding core sequences of binding peptides corresponding to the alleles, S2, establishing a neural network model based on fusion of a convolution module and a Transform module, and S3, establishing a neural network model based on fusion of the convolution module and the Transform module, the method comprises the following steps: S1, extracting two frequency characteristic tensors from S11 and S12, taking the two frequency characteristic tensors extracted in S11 and S12 as double inputs, and finally obtaining probability distribution of 20 amino acids at each position of each sequence, and S3, according to an output result of a neural network model, carrying out random sampling according to the probability, and generating a binding core sequence of MHCII-peptide meeting target distribution. According to the method, evolutionary information such as sequence position amino acid frequency (first-order conservative analysis) and combined frequency (second-order conservative analysis) of amino acid pairs is introduced to design a new short peptide sequence, the problem that short peptides cannot be designed based on structures is solved, and the reliability of short peptide sequence design based on evolutionary information is provided.

The invention relates to the field of protein-polypeptide interaction prediction in bioinformatics, in particular to a protein-polypeptide binding site prediction method based on graph attention and multi-head attention. The method mainly comprises the following steps: (1) collecting protein and polypeptide compound PDB structure information from an RCSB PDB database, and extracting sequence information of the protein and polypeptide compound PDB structure information; (2) extracting protein sequence information by using IUPred2, ProtBERT and ESM-2 (Extensible Subscriber for Mobile Communications); a ProtBERT method and an Integer method are used for extracting polypeptide sequence information; the method comprises the following steps: extracting protein structure information through biopython; (3) establishing a GAT model with residual connection to analyze a protein structure, and extracting features between amino acid nodes; (4) constructing a Circulate Block module, and carrying out deep extraction and fusion on protein and polypeptide information through four layers of Mti-head Attention and Dual Attention; and (5) finally, through a Final Attention, a linear layer and a Softmax layer, mapping the features to two dimensions to represent the interaction probability of each residue site.

The invention provides a method for predicting binding affinity of human leukocyte antigen I-type molecules and peptide fragments, and a construction method of the method comprises the following steps: acquiring antigen binding site residues of the human leukocyte antigen I-type molecules, and extracting antigen binding region sequences of the human leukocyte antigen I-type molecules through secondary multi-sequence alignment; respectively generating a human leukocyte antigen class I molecule coding matrix and a peptide fragment coding matrix based on the paired human leukocyte antigen class I molecule-peptide fragment; and then constructing a model of a convolutional neural network to quantify the binding affinity score of the human leukocyte antigen class I molecule and the peptide fragment. The invention develops a method for predicting binding affinity of human leukocyte antigen class I molecules and peptide fragments based on a convolutional neural network by combining physicochemical characteristics of amino acids, complementary epitope sequences of the human leukocyte antigen class I molecules and an interaction relationship among the sequences.

The invention discloses an HLA and antigen peptide combination prediction method based on interactive attention, and belongs to the technical field of computational biology. The method comprises the following steps: 1, collecting HLA allele and unique peptide fragment data, and constructing an HLA and antigen peptide binding data set; 2, constructing an HLA and antigen peptide binding prediction model, and training the prediction model by using the HLA and antigen peptide binding data set to obtain a trained prediction model; and step 3, inputting the HLA sequence and the antigen peptide sequence into the prediction model to obtain a prediction result of combination of the HLA and the antigen peptide. According to the method, prediction tasks based on a sequence and a structure are integrated into a unified model, and the potential of the pHLA about the sequence and the structure is analyzed and predicted. Compared with an existing method, the two-dimensional evaluation provides a more comprehensive antigen immunogenicity view angle, and a new insight is provided for the quality of a new antigen for triggering an immunoreaction.

The invention relates to the field of immunity, in particular to a T cell receptor with improved affinity, a nucleic acid molecule, a carrier, a cell and a medicine containing the T cell receptor, the nucleic acid molecule, the carrier and the cell for treating tumors. The T cell receptor includes a TCR [alpha] chain variable region and a TCR [beta] chain variable region, which have activity to bind to a KRAS G12V epitope and an HLA-A * 11 complex, and the TCR [alpha] chain variable region includes CDR1 [alpha], CDR2 [alpha] and CDR3 [alpha] complementarity determining regions, and the TCR [beta] chain variable region includes CDR1 [beta], CDR2 [beta] and CDR3 [beta] complementarity determining regions. The TCR provided by the invention has high-affinity target antigen peptide binding capacity, remarkably improves the target cell recognition capacity, shows good activation and killing activity, and shows high technical value and clinical application potential.

Described herein are compositions and methods comprising high molecular weight hyaluronic acid (high MW HA). In some embodiments, high MW HA is formulated in combination with one or more peptides. In some embodiments, the peptides comprise an octapeptide with amino acid sequence features found in collagen and / or elastin.

The invention provides a synthesis method of tilpotide, which comprises the following steps: dividing a target peptide chain into six fragments, and adopting bis (4-C18-C28 alkoxy phenyl) methylamine, 2, 4-bis (18-C28 alkoxy)-benzyl alcohol and NH2-Asp (OTAG)-OR1 as hydrophobic label carriers to assist synthesis. A side chain carboxyl group of aspartic acid is innovatively used as an anchoring position of a hydrophobic label, a new fragment connection route is designed, a full-protection tilpotide conjugate is synthesized through a multi-label synergistic effect, and finally a protecting group and a label are removed by using a TFA lysate. Compared with a solid-phase synthesis method, the method is carried out in a homogeneous reaction, the dosage of amino acid and the condensing agent is reduced to 1-1.2 times from 2-3 times, and the cost is remarkably reduced. Compared with an existing hydrophobic labeling method, the method has the advantages that multiple labels can be introduced to serve as protecting groups, the yield and purity of synthesis of medium-chain and long-chain polypeptides are improved, meanwhile, the problem of hydrophobicity attenuation caused by peptide chain extension is solved, and the green chemical process requirement is met.

In one aspect, antibodies that bind to subdomain II of human HER2 are provided. In another aspect, antibodies comprising a light chain polypeptide that pairs with both a heavy chain polypeptide for binding to subdomain II of human HER2 and a heavy chain polypeptide for binding to subdomain IV of human HER2 are provided. In a further aspect, antibodies that bind to both subdomain II and subdomain IV of human HER2 comprising a common light chain polypeptide are provided. Methods of treating a cancer or treating brain metastasis of a cancer using these antibodies are also provided.

The present invention relates to peptide conjugates of cytotoxins such as topoisomerase I inhibitors which are useful for the treatment of diseases such as cancer.

Systems and methods include techniques associated with one or more machine learning systems to predict peptide binding interactions for a relevant target. The one or more machine learning systems may be used to generate a ranked set of results that can be tested and then used to retrain the one or more machine learning systems as part of a validation process. The trained model may then be deployed to predict peptides for a given target condition.

The invention discloses a preparation method and application of GHK oligopeptide, and belongs to the technical field of biology. According to the method, a nucleotide sequence of the GHK polypeptide is obtained by designing tandem repeat GHK polypeptide ([GHK] 63) and combining preferred codons of bacillus subtilis to optimize a polypeptide coding gene. The GHK oligopeptide is subjected to recombinant expression in bacillus subtilis by utilizing a genetic engineering technology, the obtained recombinant protein is not easy to form an inclusion body and does not contain endotoxin, and the high-yield GHK oligopeptide is obtained after separation, purification and protease digestion treatment. According to the GHK oligopeptide preparation method provided by the invention, extra optimization treatment does not need to be carried out on tandem repeat GHK polypeptides, the yield of the GHK oligopeptide is improved, the whole production process is simplified, the cost is low, and the method is suitable for large-scale production of blue copper peptides and has wide application prospects in the fields of medicines, medical beauty and the like.

The invention relates to the field of immunity, in particular to a T cell receptor and application thereof in detecting, diagnosing, preventing, relieving or treating KRAS G12V mutation positive diseases and / or symptoms. The present invention provides an affinity enhanced TCR or a fragment thereof, the CDR3 [alpha] of the affinity enhanced TCR comprising an amino acid substitution at the V106 and / or I117 position relative to the CDR3 [alpha] of the parent TCR. The TCR provided by the invention has high-affinity target antigen peptide binding ability, can significantly improve the target cell recognition ability, can mediate the specific killing effect of effector cells on antigen-positive target cells, and does not have allogeneic reaction on different types of HLA (human leukocyte antigen). The KRAS G12V cell line can be used for treating various KRAS G12V positive cancers, provides an important tool for cell therapy, and shows high technical value and clinical application potential.

The invention relates to a nerve-targeted imaging nano fluorescent probe constructed by a near-infrared two-region aggregation-induced emission material and NP41 polypeptide as well as a preparation method and application of the nerve-targeted imaging nano fluorescent probe, belongs to the technical field of medical image contrast agents, and particularly relates to a nerve-targeted imaging nano fluorescent probe constructed by combining a near-infrared two-region fluorescent material TTB with AIE characteristics and a nerve-targeted peptide NP41. The invention also relates to a preparation method of the fluorescent probe and application of the fluorescent probe in long-term continuous imaging of central and peripheral nerve living bodies.

The present disclosure provides a polypeptide complex comprising a target binding polypeptide that binds to a molecule on a target cell or a molecule in an extracellular matrix (ECM); and small latent complexes comprising in particular a dimer latent related polypeptide (LAP) or a fragment or derivative thereof, and a dimer mature transforming growth factor beta (TGF beta) family polypeptide or a fragment or derivative thereof. Polypeptides (e.g., fusion polypeptides), and related polynucleotides, vectors, cells, and pharmaceutical compositions are also provided. Also provided are methods of treating subjects using, for example, these polypeptide complexes and / or these fusion polypeptides or pharmaceutical compositions thereof.

The present invention relates to the preparation and application of biological peptides, and in particular to a mussel peptide and its application in the preparation of uric acid-lowering products. The amino acid sequence is shown in SEQ ID NO.1‑4. The present invention prepares mussel polypeptides by composite enzyme-directed enzymatic hydrolysis and membrane separation and purification technology, and screens out four novel polypeptides with potential biological activity by combining LC‑MS / MS analysis and activity prediction. Molecular docking and cell experiments have confirmed that these four polypeptides can specifically inhibit GLUT9 protein activity and reduce uric acid levels; animal experiments have further verified their efficacy in lowering uric acid, providing a scientific basis for the high-value development of mussel resources and the development of functional uric acid-lowering products.

Provided herein are Camptothecin Conjugates, Camptothecin-Linker Compounds, Camptothecin Compounds, intermediates thereof, and method of preparing the same. Also provided herein are methods of treating cancer and autoimmune diseases with the Conjugates described herein.

The present disclosure provides compositions and methods for conjugating a target polypeptide and a target oligonucleotide. More particularly, the present disclosure provides compositions and methods for making and using a recombinant protein harboring a domain recognizing a nucleic acid and a domain capable of binding and crosslinking with antigen-binding polypeptides.

Provided herein are computer-implemented methods of generating a disease map of a population. In some embodiments, the methods include applying a clustering algorithm to a set of weight and bias values of a trained electronic neural network to generate the disease map of the population. In some embodiments, the electronic neural network has been trained on training data that comprises representations of peptide sequence and binding value pair data sets obtained from reference subjects in the population in which a given peptide sequence and binding value pair data set comprises peptide sequence information and peptide binding values of antibodies to peptides that comprises the peptide sequence information. In some embodiments, the antibodies are from a sample obtained from a given reference subject in the population and are indicative of one or more disease states. Related systems, computer readable media, and additional methods are also provided.

The invention relates to the technical field of immune carriers, in particular to immune carrier microspheres loaded with individualized MHC-II binding polypeptide and vaccine preparation and application of the immune carrier microspheres loaded with the individualized MHC-II binding polypeptide. The core microsphere is loaded with individualized MHC-II binding polypeptide, the sequence of the MHC-II binding polypeptide is obtained by predicting and screening based on an HLA genotyping result, and each HLA allele corresponds to at least one high-affinity MHC-II binding polypeptide; and the shell is a glucan or other polymer coating layer. The preparation method has the advantages that the T epitope and the B epitope are separately subjected to immune competitive inhibition inside and outside the microspheres, so that a better immune effect is obtained. The antibody avoids cross reaction side effects; carrier molecule diversity is reduced, and side effects caused by T cell over-activation are avoided; th1 epitopes and Th2 epitopes can be contained in the microspheres, so that antibody immunity and T cell immunity functions are generated; the particle size of the microspheres is controllable, and the immunologic function can be achieved without adjuvants.

A humanized monoclonal antibody that binds to an advanced glycation end-product-modified protein or peptide on a cell comprises a heavy chain and a light chain. The antibody binds a carboxymethyllysine-modified protein or peptide. A composition comprises a humanized monoclonal antibody that binds to an advanced glycation end-product-modified protein or peptide on a cell and a pharmaceutically acceptable carrier.

The present disclosure relates to T-cell receptors (TCRs) that bind to tumor-associated antigens (TAA) for targeting cancer cells, T-cells expressing them, methods for producing them, and methods for treating cancers using them. In particular, the present disclosure relates to TCRs and variants thereof that bind to HLA class I or II molecules with a peptide, such as IGF2BP3-001 having the amino acid sequence KIQEILTQV (SEQ ID NO:1). The present disclosure further relates to peptides, proteins, nucleic acids, and cells for use in immunotherapeutic methods. In particular, the present disclosure relates to cancer immunotherapy.The present disclosure further relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides, which can for example serve as active pharmaceutical ingredients in vaccine compositions that stimulate anti-tumor immune responses or stimulate T-cells ex vivo and deliver them to patients. Peptides bound to major histocompatibility complex (MHC) molecules, or the peptides themselves, can also be targets of antibodies, soluble T-cell J receptors and other binding molecules.

Disclosed herein is a delivery vehicle based on DNA-inspired Janus based nanotubes (JBNTs) for anti-viral treatment. The nanoparticles (NPs) are based the JBNTs conjugated with targeting moieties such as small molecules, aptamers, and peptides.

An example composition includes one or more binding agents and one or more solid-phase substrates bound to the one or more binding agents. The one or more binding agents are or include: (i) a peptide including at least part of a full-length protein, where the peptide is for binding to an antibody, or (ii) a molecule that mimics an ability of the peptide to bind to the antibody.

The present invention relates to a peptide binding to OTUB1 and a use thereof. A peptide of a specific sequence having the property of binding to OTUB1 is observed to exhibit an anticancer effect on cancer cells without affecting the cell growth of normal cells, and thus can be usefully used as a composition for preventing, treating, or alleviating cancer diseases.

The invention is directed to a method for detecting at least one target peptide by binding to a MHC protein by providing a plurality of different MHC proteins with placeholder peptides labelled with at least one fluorescent marker thereby obtaining a plurality of labelled MHC proteins.

Antibodies that bind human beta-amyloid peptide, methods of detecting, measuring and treating amyloidogenic disorders with said antibodies, pharmaceutical compositions comprising the antibodies and methods of manufacture are provided.

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

The filed of the present invention relates to immunotherapeutic peptides, peptide binding agents, and their use, for example, in the immunotherapy of cancer.

The present invention relates to a peptide of 12 to 30 amino acids, said peptide comprising the sequence SEQ ID NO: 1 represented by:(SEQ ID NO: 1)V-X1-X2-R-X3-E-W-X4-X5-X6-Y-W,wherein each of X1, X2, X3, X4, X5, and X6 independently corresponds to any amino acid, andwherein said peptide binds to the EGF receptor variant III (EGFRvIII), as well as products incorporating such peptide and uses thereof.

Provided, as an anti-SARS-CoV-2 peptide drug, is an optimal salt form of a peptide that binds to a receptor-binding domain (RBD) in SARS-CoV-2.　A sodium or potassium salt of a peptide according to the present invention has, in a direction from an N-terminus to a C-terminus, a first region including a first helix and a second region including a second helix. The first region and the second region each include a site that binds to a receptor-binding domain (RBD) in SARS-CoV-2. A bond is formed between amino acid residues within five residues on the N-terminus side in the sequence of the site that binds to the receptor-binding domain (RBD) in SARS-CoV-2 in the first region and amino acid residues within five residues on the C-terminus side in the sequence of the site that binds to the receptor-binding domain (RBD) in SARS-CoV-2 in the second region, and the peptide binds to the receptor-binding domains (RBD) in SARS-CoV-2.